Stock listing

Frankfurt:B1Q NRX Pharmaceuticals, Inc. Aktie

German listing (Frankfurt) of NRX Pharmaceuticals, Inc. · home listing NASDAQ:NRXP

Follow NRX Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · FWB:B1Q

€2.85 EUR +0.57 (+24.7%)

Close on Oct 30, 2026

Day range
€2.59 – €2.85 EUROct 30, 2026
Market cap
€123.4M EURAt the close on Oct 30, 2026 · price × 43.30M shares outstanding
NRX Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NRXP · Home$2.27 USD-0.39 (-14.7%)15,536,405$2.83$2.84$2.11$2.66Close on Oct 30, 2026
Frankfurt:B1Q€2.85 EUR+0.565 (+24.7%)—€2.725€2.85€2.59€2.285Close on Oct 30, 2026
Ticker
Frankfurt:B1Q
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2026 Earnings Call

    Mon, Aug 17, 2026 · 4:30 PM ET

    Watch Transcript

  • NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2026 Earnings Call

    Mon, May 18, 2026 · 8:00 AM ET

    Watch Transcript

  • NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2025 Earnings Call

    Tue, Mar 24, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

NRx Pharmaceuticals (Nasdaq: NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date

Oct 30, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine

Oct 29, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

Oct 19, 2026

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

Oct 15, 2026

NRx Defense Systems, an NRx Company (Nasdaq: NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

Sep 30, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

Sep 15, 2026

GeNeuro, Inc., an NRx Company (Nasdaq: NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

Sep 14, 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

Sep 11, 2026

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

Sep 8, 2026

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

Aug 7, 2026

All NRX Pharmaceuticals, Inc. news

Decks

NRX Pharmaceuticals, Inc. on 6ix

News releases
54 in the last 12 months · 273 in all · newest Oct 30, 2026 · oldest 2021
Calls
20 calls with a replay · 20 with a transcript · latest Aug 17, 2026
Decks
5 decks · latest Sep 14, 2026

Where NRX Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NRXP · Home listingNASDAQUnited StatesUSD
LS Exchange:A4091KLS ExchangeGermanyEUR
Lang & Schwarz:A4091KLang & SchwarzGermanyEUR
BOATS:NRXPBOATSUnited StatesUSD
gettex:B1QgettexGermanyEUR
Tradegate:B1QTradegateGermanyEUR
Frankfurt:B1Q · This pageFrankfurtGermanyEUR
Hamburg:B1QHamburgGermanyEUR
Munich:B1QMunichGermanyEUR

Log in to ask 6ix AI your own questions about NRX Pharmaceuticals, Inc.